martes, 4 de septiembre de 2018

Top 10 Global CROs 2018 IGEAhub

.



Ranking and complete review of the 10 Best Global Contract Research Organizations (CROs) in 2018



In 2017, the global CRO services market is estimated to be valued at USD 36.27 Billion and projected to grow at a CAGR of 7.6% from USD 39.13 Billion in 2018 to reach USD 56.34 Billion by 2023

Globally more than 1,100 CRO companies are active in 2017. 
The global CRO market is centralized with the top 10 companies that generated collective total revenue of USD 34.514 billion in 2017 (including reimbursed out-of-pocket revenue). 
The global contract research market is growing at a strong rate as increased dependence of pharmaceutical, biopharmaceutical and medical device companies seen due to increased outsourcing of R&D activities, increased R&D expenditures and, increasing number of clinical trials.


The leaders in this market include a mix of public-listed and privately held organizations. 
Recent collaborations by CRO companies with government agencies and non-profit health organizations has proved that CROs are not just clinical service providers but actively involved in the new drug development process, and immensely contributing to the development of new products and helping advancement in healthcare outcomes.

A ranking system was developed for the top-10 global clinical research organizations. 
A score statistic was developed to determine the rank of each organization. 

  • Revenues (70%), 
  • annual Revenue growth 2016 to 2017 (10%), 
  • net income (5%), 
  • expenses ratios (5%), 
  • revenue per Employee (5%), and 
  • scope of service portfolio (5%) 

were the key input criteria used to calculate the score statistic for and every organization was assigned a score for each of these key input criteria. 
Different weights were assigned to each rank. 
A weighted sum of the scores was used to arrive at the final score statistic for each organization. 
The final score statistic represents the financial health, competitive advantage, and activity status of each organization in the clinical trials domain.


No hay comentarios: